Identification of inhibitors for single-stranded DNA-binding proteins in eubacteria

Jason G. Glanzer, Jennifer L. Endres, Brendan M. Byrne, Shengqin Liu, Kenneth W Bayles, Gregory G Oakley

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objectives: The increasing threat of drug-resistant bacteria establishes a continuing need for the development of new strategies to fight infection. We examine the inhibition of the essential single-stranded DNA-binding proteins (SSBs) SSBA and SSBB as a potential antimicrobial therapy due to their importance in DNA replication, activating the SOS response and promoting competence-based mechanisms of resistance by incorporating new DNA. Methods: Purified recombinant SSBs from Gram-positive (Staphylococcus aureus and Bacillus anthracis) and Gram-negative (Escherichia coli and Francisella tularensis) bacteria were assessed in a high-throughput screen for inhibition of duplex DNA unwinding by small molecule inhibitors. Secondary electrophoretic mobility shift assays further validated the top hits that were then tested for MICs using in vitro assays. Results:We have identified compounds that show cross-reactivity in vitro, aswell as inhibition of both F. tularensis and B. anthracis SSBA. Five compounds were moderately toxic to at least two of the four bacterial strains in vivo, including two compounds that were selectively non-toxic to human cells, 9-hydroxyphenylfluoron and purpurogallin. Three of the SSBA inhibitors also inhibited S. aureus SSBB in Gram-positive bacteria. Conclusions: Results from our study support the potential for SSB inhibitors as broad-spectrum antibacterial agents, with dual targeting capabilities against Gram-positive bacteria.

Original languageEnglish (US)
Pages (from-to)3432-3440
Number of pages9
JournalJournal of Antimicrobial Chemotherapy
Volume71
Issue number12
DOIs
StatePublished - Jan 1 2016

Fingerprint

DNA-Binding Proteins
Francisella tularensis
Bacillus anthracis
Gram-Positive Bacteria
Bacteria
Staphylococcus aureus
Poisons
DNA
Electrophoretic Mobility Shift Assay
DNA Replication
Mental Competency
Escherichia coli
Anti-Bacterial Agents
Infection
Pharmaceutical Preparations
Inhibition (Psychology)
In Vitro Techniques
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Identification of inhibitors for single-stranded DNA-binding proteins in eubacteria. / Glanzer, Jason G.; Endres, Jennifer L.; Byrne, Brendan M.; Liu, Shengqin; Bayles, Kenneth W; Oakley, Gregory G.

In: Journal of Antimicrobial Chemotherapy, Vol. 71, No. 12, 01.01.2016, p. 3432-3440.

Research output: Contribution to journalArticle

Glanzer, Jason G. ; Endres, Jennifer L. ; Byrne, Brendan M. ; Liu, Shengqin ; Bayles, Kenneth W ; Oakley, Gregory G. / Identification of inhibitors for single-stranded DNA-binding proteins in eubacteria. In: Journal of Antimicrobial Chemotherapy. 2016 ; Vol. 71, No. 12. pp. 3432-3440.
@article{77fbebf398484fc2883d2ad37ac64d25,
title = "Identification of inhibitors for single-stranded DNA-binding proteins in eubacteria",
abstract = "Objectives: The increasing threat of drug-resistant bacteria establishes a continuing need for the development of new strategies to fight infection. We examine the inhibition of the essential single-stranded DNA-binding proteins (SSBs) SSBA and SSBB as a potential antimicrobial therapy due to their importance in DNA replication, activating the SOS response and promoting competence-based mechanisms of resistance by incorporating new DNA. Methods: Purified recombinant SSBs from Gram-positive (Staphylococcus aureus and Bacillus anthracis) and Gram-negative (Escherichia coli and Francisella tularensis) bacteria were assessed in a high-throughput screen for inhibition of duplex DNA unwinding by small molecule inhibitors. Secondary electrophoretic mobility shift assays further validated the top hits that were then tested for MICs using in vitro assays. Results:We have identified compounds that show cross-reactivity in vitro, aswell as inhibition of both F. tularensis and B. anthracis SSBA. Five compounds were moderately toxic to at least two of the four bacterial strains in vivo, including two compounds that were selectively non-toxic to human cells, 9-hydroxyphenylfluoron and purpurogallin. Three of the SSBA inhibitors also inhibited S. aureus SSBB in Gram-positive bacteria. Conclusions: Results from our study support the potential for SSB inhibitors as broad-spectrum antibacterial agents, with dual targeting capabilities against Gram-positive bacteria.",
author = "Glanzer, {Jason G.} and Endres, {Jennifer L.} and Byrne, {Brendan M.} and Shengqin Liu and Bayles, {Kenneth W} and Oakley, {Gregory G}",
year = "2016",
month = "1",
day = "1",
doi = "10.1093/jac/dkw340",
language = "English (US)",
volume = "71",
pages = "3432--3440",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - Identification of inhibitors for single-stranded DNA-binding proteins in eubacteria

AU - Glanzer, Jason G.

AU - Endres, Jennifer L.

AU - Byrne, Brendan M.

AU - Liu, Shengqin

AU - Bayles, Kenneth W

AU - Oakley, Gregory G

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Objectives: The increasing threat of drug-resistant bacteria establishes a continuing need for the development of new strategies to fight infection. We examine the inhibition of the essential single-stranded DNA-binding proteins (SSBs) SSBA and SSBB as a potential antimicrobial therapy due to their importance in DNA replication, activating the SOS response and promoting competence-based mechanisms of resistance by incorporating new DNA. Methods: Purified recombinant SSBs from Gram-positive (Staphylococcus aureus and Bacillus anthracis) and Gram-negative (Escherichia coli and Francisella tularensis) bacteria were assessed in a high-throughput screen for inhibition of duplex DNA unwinding by small molecule inhibitors. Secondary electrophoretic mobility shift assays further validated the top hits that were then tested for MICs using in vitro assays. Results:We have identified compounds that show cross-reactivity in vitro, aswell as inhibition of both F. tularensis and B. anthracis SSBA. Five compounds were moderately toxic to at least two of the four bacterial strains in vivo, including two compounds that were selectively non-toxic to human cells, 9-hydroxyphenylfluoron and purpurogallin. Three of the SSBA inhibitors also inhibited S. aureus SSBB in Gram-positive bacteria. Conclusions: Results from our study support the potential for SSB inhibitors as broad-spectrum antibacterial agents, with dual targeting capabilities against Gram-positive bacteria.

AB - Objectives: The increasing threat of drug-resistant bacteria establishes a continuing need for the development of new strategies to fight infection. We examine the inhibition of the essential single-stranded DNA-binding proteins (SSBs) SSBA and SSBB as a potential antimicrobial therapy due to their importance in DNA replication, activating the SOS response and promoting competence-based mechanisms of resistance by incorporating new DNA. Methods: Purified recombinant SSBs from Gram-positive (Staphylococcus aureus and Bacillus anthracis) and Gram-negative (Escherichia coli and Francisella tularensis) bacteria were assessed in a high-throughput screen for inhibition of duplex DNA unwinding by small molecule inhibitors. Secondary electrophoretic mobility shift assays further validated the top hits that were then tested for MICs using in vitro assays. Results:We have identified compounds that show cross-reactivity in vitro, aswell as inhibition of both F. tularensis and B. anthracis SSBA. Five compounds were moderately toxic to at least two of the four bacterial strains in vivo, including two compounds that were selectively non-toxic to human cells, 9-hydroxyphenylfluoron and purpurogallin. Three of the SSBA inhibitors also inhibited S. aureus SSBB in Gram-positive bacteria. Conclusions: Results from our study support the potential for SSB inhibitors as broad-spectrum antibacterial agents, with dual targeting capabilities against Gram-positive bacteria.

UR - http://www.scopus.com/inward/record.url?scp=85026295021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026295021&partnerID=8YFLogxK

U2 - 10.1093/jac/dkw340

DO - 10.1093/jac/dkw340

M3 - Article

C2 - 27609050

AN - SCOPUS:85026295021

VL - 71

SP - 3432

EP - 3440

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - 12

ER -